180 Degree Capital
7 N. Willow Street Suite 4B, Montclair, NJ, 07042, United States
Overview
With some 25 tiny technology companies in our portfolio, Harris & Harris Group, Inc.®, is one of the most active nanotechnology investors in the world. They have funded companies developing nanoscale-enabled solutions in solid state lighting, emerging memory devices, printable electronics, material science discovery and mass-manufacturing, organic-inorganic hybrids, next-generation semiconductor devices and equipment, thermoelectric, photovoltaic and battery technologies, as well as in various life-science applications of nano-structured materials. They participate in venture capital syndicates in most of their investments, alongside top-tier venture capital firms as well as strategic (corporate) investors. Increasingly, Harris & Harris Group is a lead investor. They believe in the classical early stage venture capital model and disciplines and that most technology-based start-ups can use all the help they can get from the diversified experiences, Rolodexes®, complimentary business networks, technical expertise, up-to-date customer connections and financial resources that a syndicate of professional venture capital investors can provide. Harris & Harris Group will invest at any stage prior to a company's initial public offering, and they will invest anywhere in the United States. Occasionally, they have also made private investments in publicly held companies (so-called "PIPE" investments). They have invested outside the United States, but rarely. Their current portfolio companies are distributed all across the country, plus one in Canada. Harris & Harris Group is looking for scientific, technological, business and execution excellence. They are attracted to markets of significant size and back passionate entrepreneurs who want to change the world with their tiny technology-enabled products. Proprietary, well-protected and highly differentiated technology is a prerequisite. But above all, they are eager to invest in companies with market-centric strategies that seek to define and dominate large product categories.
- Total investments
- 3
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Venture Capital
Investment portfolio
- Magnolia NeuroSciences
Participated · Series A · Aug 2018
Magnolia Neurosciences is developing a new class of neuroprotective therapies that target specific components of programmed cell death to preserve brain tissue. The company’s programs are built on discoveries from The University of Texas MD Anderson Cancer Center and the Neurodegeneration Consortium. Preclinical data cited in the articles show that blocking these pathways preserves neurons and leads to enhanced memory in animal models. Magnolia aims to develop potent, highly selective neuroprotective therapies with compelling preclinical pharmacologic profiles and to obtain clinical proof of concept rapidly. The company was launched with a $31 million Series A investment and is positioned to address unmet needs across Alzheimer’s disease, neuronal injury, and other CNS conditions. Its offices are located in the Alexandria Center for Life Science in New York City.
- NGX Bio
Led · Equity · Aug 2017
Ngx Bio is a San Francisco, CA–based marketplace for online DNA sequencing services, founded in 2014 and led by President and CEO Denis Kourakin. The platform matches customers' sequencing needs with providers who have available sequencing capacity and enables purchases via online ordering tools. It offers a wide range of sequencing services for both human and non-human samples and serves customers globally. The company closed a $3.0 million funding round and said it will use the funds to continue to expand operations. Participants in the round included 180 Degree Capital Corp., Third Kind Venture Capital, Lateral Capital, the Band of Angels and the Berkeley Angel Network, among others. Ngx Bio aims to provide streamlined, online access to next-generation sequencing services for clients worldwide.
- ORIG3N
Participated · Equity · Jun 2017
Orig3n is a Boston-based biotech research company focused on genetics and regenerative medicine. It provides consumers access to genetic information to enable proactive, personalized health choices and conducts R&D into cell therapies. The company invests in cellular science to develop personalized therapies for repairing tissue damage and disease. Orig3n maintains a large allogeneic bank of cells that is HLA-matched to 90% of the U.S. population, which underpins its regenerative-medicine programs. It plans to use recent funding to expand domestically and internationally and to continue R&D to advance its regenerative treatments. As of the Series B, Orig3n has raised over $50 million since its 2014 founding. ORIG3N focuses on genetics and regenerative medicine, offering a line of direct-to-consumer genetic tests while advancing cellular science to develop personalized therapies. The company operates what it describes as a fully-matched allogeneic cell bank and is intensifying research into cell therapies. ORIG3N emphasizes community‑driven, patient-fueled research and cultivates engagement through events and educational initiatives. Management says the company is increasingly consumer-facing and aims to accelerate the future of regenerative medicine. ORIG3N was founded in 2014 and is positioning its research and community assets to support therapeutic development. Financially, the company has raised over $30 million in capital to date. Orig3n is a Boston, MA-based biotech company that develops a disease-modeling platform targeting rare and genetically inherited diseases using iPSC-derived differentiated cells. The company closed a $12.5m Series A financing to advance its programs. It will use the funds to launch LifeSystems™ cellular models created from its LifeCapsule™ bio-repository. Orig3n launched the LifeCapsule bio-repository, a living database and large bank of induced pluripotent stem cells to which anyone can contribute. The platform is intended to advance screening projects and deliver data to inform therapeutic decisions, aiming to replace trial-and-error approaches to treating disease. Orig3n was founded in 2014 by Robin Y. Smith. ORIG3N, based in Boston, MA, is developing a disease-modeling platform targeting rare genetically inherited diseases. Led by CEO and co-founder Robin Y. Smith, the company’s core product is the Life Capsule™, a bio-repository open to public contribution. The Life Capsule collects a small amount of blood and reprograms cells into induced pluripotent stem cells (iPSCs). These iPSCs are used for disease modeling outside the body to support critical medical research and potential individualized therapy. The company intends to use the newly raised funds to expand its Life Capsule offering. ORIG3N recently raised $3.1M in funding from institutional backers.